Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Survanta Market Expected To Reach $ Billion By 2030 At % CAGR
Growth during the historical timeframe was driven by escalating rates of preterm births, a growing recognition of neonatal respiratory distress syndrome, the broader establishment of neonatal intensive care units, enhanced survival outcomes among premature newborns, and the expanded use of surfactant therapy in clinical settings.
Expanding neonatal healthcare access in emerging markets, growing emphasis on advanced care technologies, continuous clinical research into lung maturation therapies, stronger demand for early intervention treatments, and enhanced neonatal drug delivery methods are expected to drive growth in the forecast period. At the same time, key trends include the rising adoption of surfactant replacement therapies, greater attention to neonatal respiratory care, worldwide expansion of NICU infrastructure, better administration techniques tailored for premature infants, and more standardized clinical protocols.
Download A Free Sample Report For Comprehensive Market Insights:
Survanta Market Demand Drivers: What Is Fueling Industry Growth?
The future expansion of the survanta market is being significantly fueled by a rising incidence of preterm births. A preterm birth is defined as delivery occurring before the 37th week of gestation, which often results in immature organ systems and elevated health vulnerabilities. Several factors contribute to the growing rate of these early deliveries, including delayed childbearing, certain lifestyle habits, a higher prevalence of chronic illnesses, and progress in reproductive technologies. Survanta plays a crucial role in managing respiratory distress syndrome (RDS), a frequent complication in preterm infants caused by a lack of lung surfactant, by enhancing pulmonary function and lowering the risk of adverse outcomes. For example, as reported by the Centers for Disease Control and Prevention in April 2025, the preterm birth rate in the United States stood at 10.41% for 2024. Consequently, this upward trend in premature births is a key driver for the expanding survanta market.
Rising financial commitments to maternal and child health are anticipated to be a significant catalyst for the survanta market’s growth in the coming period. This field encompasses the overall health and welfare of mothers during gestation, delivery, and the postnatal phase, along with children’s early developmental stages. Such increased investment is motivated by the urgency to lower maternal and infant death rates, enhance healthcare accessibility, and foster lasting social and economic advantages. Allocating funds to maternal and child health facilitates access to critical therapies like survanta, which can decrease newborn fatalities from respiratory distress syndrome. As an illustration, the American Hospital Association disclosed in September 2024 that the Department of Health and Human Services had dedicated more than $558 million to maternal health, with $440 million directed toward home visiting programs and $118.5 million for CDC initiatives. Hence, these growing investments are fostering the expansion of the survanta market.
The survanta market’s forward momentum is expected to be driven by an escalating volume of infant hospitalizations. This increase in admissions for newborns is linked to several elements, such as a higher frequency of premature births, more occurrences of neonatal and breathing-related illnesses, enhanced survival rates that demand more intricate medical attention, and improved availability of hospital services. Survanta is employed during these hospital stays to address respiratory distress syndrome (RDS) in premature babies, thereby improving lung performance and decreasing the likelihood of complications. To illustrate, data from the UK’s Office for Health Improvement and Disparities in May 2024 showed that admissions for infants under 14 days rose from 81.6 per 1,000 people in the 2022 fiscal year to 84.8 per 1,000 in the 2023 fiscal year. Therefore, the rising trend of infant hospital admissions is set to boost the survanta market.
Survanta Market Segments: Where Are The Largest Growth Opportunities?
The survanta market covered in this report is segmented –
1) By Indication: Respiratory Distress Syndrome (RDS), Meconium Aspiration Syndrome (MAS), Bronchopulmonary Dysplasia (BPD), Acute Respiratory Failure, Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Public Health Clinics
3) By End-User: Pediatric
Survanta Market Major Participants And Competitive Dynamics
Major companies operating in the survanta market are AbbVie Ltd.
Access The Complete Survanta Market Report:
Survanta Market Geographic Distribution And Regional Opportunities
North America was the largest region in the survanta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the survanta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model